AU2017369207C1 - A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent - Google Patents

A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent Download PDF

Info

Publication number
AU2017369207C1
AU2017369207C1 AU2017369207A AU2017369207A AU2017369207C1 AU 2017369207 C1 AU2017369207 C1 AU 2017369207C1 AU 2017369207 A AU2017369207 A AU 2017369207A AU 2017369207 A AU2017369207 A AU 2017369207A AU 2017369207 C1 AU2017369207 C1 AU 2017369207C1
Authority
AU
Australia
Prior art keywords
nucleic acid
amino
reactant
modified
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017369207A
Other languages
English (en)
Other versions
AU2017369207B2 (en
AU2017369207A1 (en
AU2017369207A9 (en
Inventor
Lucas Bethge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptarion Biotech AG
Original Assignee
Aptarion Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptarion Biotech AG filed Critical Aptarion Biotech AG
Publication of AU2017369207A1 publication Critical patent/AU2017369207A1/en
Publication of AU2017369207A9 publication Critical patent/AU2017369207A9/en
Assigned to TME Pharma AG reassignment TME Pharma AG Amend patent request/document other than specification (104) Assignors: NOXXON PHARMA AG
Publication of AU2017369207B2 publication Critical patent/AU2017369207B2/en
Application granted granted Critical
Publication of AU2017369207C1 publication Critical patent/AU2017369207C1/en
Assigned to APTARION BIOTECH AG reassignment APTARION BIOTECH AG Request for Assignment Assignors: TME Pharma AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10Modifications characterised by
    • C12Q2525/205Aptamer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2017369207A 2016-11-30 2017-11-30 A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent Active AU2017369207C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16201391 2016-11-30
EP16201391.6 2016-11-30
PCT/EP2017/001399 WO2018099600A1 (en) 2016-11-30 2017-11-30 A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent

Publications (4)

Publication Number Publication Date
AU2017369207A1 AU2017369207A1 (en) 2019-05-23
AU2017369207A9 AU2017369207A9 (en) 2019-07-25
AU2017369207B2 AU2017369207B2 (en) 2023-12-14
AU2017369207C1 true AU2017369207C1 (en) 2024-06-27

Family

ID=57544196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017369207A Active AU2017369207C1 (en) 2016-11-30 2017-11-30 A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent

Country Status (14)

Country Link
US (1) US11459352B2 (enExample)
EP (1) EP3548089B1 (enExample)
JP (1) JP7113825B2 (enExample)
KR (1) KR102611562B1 (enExample)
CN (1) CN110121363B (enExample)
AU (1) AU2017369207C1 (enExample)
BR (1) BR112019009373A8 (enExample)
CA (1) CA3043478C (enExample)
DE (1) DE17829597T1 (enExample)
ES (1) ES2975373T3 (enExample)
MX (1) MX2019006363A (enExample)
RU (1) RU2765027C2 (enExample)
SG (1) SG10202105648XA (enExample)
WO (1) WO2018099600A1 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495881C (en) 2002-08-19 2014-07-08 The President And Fellows Of Harvard College Evolving new molecular function
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
WO2005042563A2 (en) * 2003-10-22 2005-05-12 Akzo Nobel N.V. Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
MX2007013760A (es) * 2005-05-04 2008-01-28 Noxxon Pharma Ag Uso novedoso de spiegelmers.
US9388457B2 (en) * 2007-09-14 2016-07-12 Affymetrix, Inc. Locus specific amplification using array probes
DE102007058713A1 (de) * 2007-12-06 2009-06-10 Evonik Goldschmidt Gmbh Silicon(meth-)acrylat-Partikel, Verfahren zu deren Herstellung sowie deren Verwendung
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素(hepcidin)結合之核酸類
CN103608042A (zh) * 2011-04-26 2014-02-26 雷加多生物科学公司 生产peg化的寡核苷酸的方法
BR112014009104A2 (pt) 2011-10-21 2017-04-18 Noxxon Pharma Ag ácidos nucleicos que se ligam ao glucagon
WO2013135359A1 (en) * 2012-03-16 2013-09-19 Merck Patent Gmbh Targeting aminoacid lipids
WO2015113776A1 (en) 2014-02-03 2015-08-06 Noxxon Pharma Ag Methods for the preparation of a polyalkoxylated nucleic acid molecule

Also Published As

Publication number Publication date
KR102611562B1 (ko) 2023-12-07
CN110121363A (zh) 2019-08-13
EP3548089B1 (en) 2023-12-27
AU2017369207B2 (en) 2023-12-14
ES2975373T3 (es) 2024-07-04
RU2019120021A (ru) 2021-01-11
AU2017369207A1 (en) 2019-05-23
KR20190088062A (ko) 2019-07-25
CA3043478C (en) 2023-07-25
EP3548089A1 (en) 2019-10-09
RU2765027C2 (ru) 2022-01-24
RU2019120021A3 (enExample) 2021-04-06
JP7113825B2 (ja) 2022-08-05
WO2018099600A9 (en) 2023-12-28
WO2018099600A1 (en) 2018-06-07
SG10202105648XA (en) 2021-06-29
WO2018099600A8 (en) 2019-07-04
CA3043478A1 (en) 2018-06-07
BR112019009373A8 (pt) 2023-04-11
US11459352B2 (en) 2022-10-04
DE17829597T1 (de) 2019-12-05
CN110121363B (zh) 2023-08-29
JP2020500519A (ja) 2020-01-16
EP3548089C0 (en) 2023-12-27
BR112019009373A2 (enExample) 2019-07-23
AU2017369207A9 (en) 2019-07-25
US20200291057A1 (en) 2020-09-17
MX2019006363A (es) 2019-11-12

Similar Documents

Publication Publication Date Title
JP7183167B2 (ja) 減少した腎クリアランスを有する多量体オリゴヌクレオチド
KR101189555B1 (ko) 폴리사카라이드 및 폴리뉴클레오티드로부터 접합체를제조하는 방법
US12043642B2 (en) Process for the purification of oligonucleotides
US8940879B2 (en) Functional molecule, functional molecule synthesizing amidite and target substance analysis method
RU2564855C2 (ru) Способ получения пэгилированных олигонуклеотидов
JP2021072823A (ja) ポリアルコキシル化核酸分子の調製のための方法
AU2017369207C1 (en) A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent
WO2010017328A2 (en) Cyclodextrin conjugates
HK40007263B (en) A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent
HK40007263A (en) A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent
US20100056612A1 (en) Molecular entities for binding, stabilization and cellular delivery of charged molecules
NL2033185B1 (en) Compounds for rna stabilisation and delivery

Legal Events

Date Code Title Description
SREP Specification republished
HB Alteration of name in register

Owner name: TME PHARMA AG

Free format text: FORMER NAME(S): NOXXON PHARMA AG

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 MAR 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 12 MAR 2024

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: APTARION BIOTECH AG

Free format text: FORMER OWNER(S): TME PHARMA AG